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Properdin is a normal serum protein that increases the production of complement activa-
tion products by binding C3b integral to convertase complexes and amplifying their activity
at the site of activation. Thereby, it not only can aid in the resolution of infection but also
contribute to tissue damage. In human sepsis, circulating complement C3 concentrations
are decreased, though C3 is described as a positive acute phase reactant. However, prop-
erdin levels in human sepsis have not been reported. In this study, serum from 81 critically
ill patients (predominately abdominal and respiratory sepsis) were analyzed for properdin
levels at defined points of their stay in the intensive care unit (ICU) and compared with
61 age and sex-matched healthy volunteers. Properdin concentrations were significantly
decreased in patients with sepsis on admission to ICU, but increased after clinical recovery
to exceed levels observed in healthy volunteers. Properdin concentrations at ICU admis-
sion were decreased in non-survivors of sepsis compared to survivors, but this did not
correlate with APACHE II score. However, pathologically low properdin levels (<7 µg/ml)
were related to increased duration of treatment.
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INTRODUCTION
Sepsis is a life threatening condition in which a systemic inflamma-
tory reaction may progress to shock, hypoperfusion of lungs, kid-
neys, and intestines and via consumption of coagulation factors to
intravascular coagulopathy. Cytokine storm, systemic macrophage
activation, complement activation, and activation of the coagula-
tion cascade are factors that drive the organism from a state of
overinflammation to immune exhaustion. The complement sys-
tem is primarily a humoral, hierarchically arranged, system in
which activation of recognition molecules is translated to enzy-
matic activity of protein complexes, which cleave C3 and C5 to
generate potent anaphylatoxins, C3a and C5a. The strength of
activation also determines cell activities, such as phagocytosis,
respiratory burst, and vascular leakage. The contribution of com-
plement activation to tissue damage in septic conditions is thought
to be so significant that attempts are made to develop therapeu-
tic blockers in order to rein in its activity (1). However, because
complement operates over a wide range of biological functions
in health and disease, choosing the window of opportunity in a
polymorphic system (2) is likely to be very difficult. In experi-
mental animal models of sepsis, however, treatment with anti-C5a
or anti-C5aR antibodies in clear relation to the defined onset of
sepsis has proven efficacious (3, 4).
The role of low levels of mannan binding lectin (MBL), one of
the lectin pathway recognition molecules, as a single determinant
in the outcome from severe shock is not clear; while studies link low
MBL levels to an increased risk of developing the systemic inflam-
matory response syndrome, others assign a beneficial effect to low
MBL levels because of the potentially reduced pro-inflammatory
reaction (5). A prospective study of septic patients in comparison
with healthy controls found depressed levels of complement C3
and elevated complement activation products C3a, Factor Bb and
C4d, during the first 2 days of intensive care treatment (6). The
observed increase in C5a in septic samples is consistent with pre-
vious work analyzed by the Bayesian inference approach (6). How-
ever, in sepsis, significant amounts of C5aR are found in serum,
most likely shed from neutrophils (7); properdin is produced by
neutrophils (8). Properdin is the only amplifier of complement
activation but there are no data on properdin levels in human sep-
sis. A genetic deficiency of properdin predisposes to death from
meningococcal septicemia in man (9), and in mice, significant
impairment of survival is observed in endotoxin shock (10).
The aim of this study was to investigate properdin concentra-
tions in critically ill patients admitted to the intensive care unit
(ICU) with sepsis, using serum samples taken during a recently
published observational study (11).
MATERIALS AND METHODS
Patients admitted to ICU at Leicester Royal Infirmary with a diag-
nosis of sepsis, and healthy volunteers matched for age and sex were
recruited, as previously described (11). Permission to measure
properdin in these samples was granted by University Hospitals
of Leicester NHS Trust (R&D reference: UHL 11348 “Properdin
and inflammatory biomarkers in sepsis”). Patients’ samples were
taken on Days 1 and 2 of ICU admission, and a further sample was
obtained after clinical recovery from sepsis. Archived, anonymized
serum samples from 81 patients (40 m/41 f; 19-87 years) and of
61 age and sex-matched volunteers (29 m/32 f; 21-85 years) were
analyzed. The origin of sepsis was as follows: abdominal n= 41,
respiratory n= 25, neutropenic n= 5, urosepsis n= 2, and a small
group of n= 8 made up of line infection (n= 2), fasciitis (n= 4),
postpartum sepsis (n= 1), and abscess (n= 1).
Properdin was determined from 1/5000 serum sample dilutions
using commercial kits (Hycult Biotech, Uden, The Netherlands),
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following the manufacturer’s protocol. Concentrations from
duplicate measurements were calculated from a standard curve set
up in duplicate. Those below the lowest dilution of the standard
curve (cut off 0.3 ng/ml) were classed as deficient (zero).
STATISTICAL ANALYSIS
Data for properdin concentrations were normally distributed and
were analyzed by an unpaired t -test between two groups. Dura-
tion of ICU or hospital stay was not normally distributed and was
compared against properdin concentrations by non-parametric
two-tailed Spearman correlation. P-values<0.05 were considered
statistically significant.
RESULTS AND DISCUSSION
Samples were available for 81, 66, and 45 patients on Days 1, 2 and
recovery, respectively. Clinical and other data have been reported
previously (11). While consecutive levels were significantly lower
at Days 1 and 2 of ICU admission compared to matched volun-
teers, levels increased significantly at clinical recovery (Table 1).
Properdin levels did not correlate with survival time in those
who succumbed within 1-3 days after admission to ICU. There
was no relationship between properdin and total white cell or
neutrophil counts. Properdin levels were significantly higher after
Table 1 | Properdin levels in sera of critically ill patients with sepsis
admitted to ICU and a healthy control group.
Group Range (µg/ml) Mean±SD
Day 1 (n=81) 0−38.8 9.0±7.6
Day 2 (n=66) 0−30.9 8.9±6.9
Clinically recovered (n=45) 2.4−51.2 22.9±11.1a,b
Volunteers (n=61) 7.6−34.10 18.4±5.5c
Day 1, survivors (n=60) 0−38.8 9.8±8.1
Day 1, non-survivors (n=21) 0−21.2 6.8±5.2
The time point of clinical recovery from sepsis was variable.
ap<0.0001 against Days 1 and 2.
bp< 0.0008 against volunteers.
cp<0.0001 against Days 1 or 2; Day 1 vs Day 2 n.s.
clinical recovery compared to healthy volunteers. At the timepoint
of clinical recovery, however, there was still biochemical evidence
of inflammation (CRP and IL-8 concentrations had not com-
pletely normalized; increased leukocyte, neutrophil and platelet
counts compared to the control group) (11). Properdin levels in
the healthy volunteers of European background analyzed as part
of this study were higher than those reported in a recent study for
healthy South East Asians (12).
The overall 30-day mortality in patients was 21/81 (25.9%). For
four patients, in whom there (reproducibly) was no antigenically
detectable properdin in their initial serum samples, no subsequent
sample existed to exclude a genetic deficiency. But, as properdin is
an x-chromosome linked gene and a primary deficiency uncom-
mon, the possibility of a gene defect does not appear likely in the
case of the two female patients. When comparing properdin levels
determined for samples obtained on day 1 of admission to ICU
between survivors and non-survivors, properdin appeared to be
lower in non-survivors but this did not reach statistical significance
(Table 1).
Properdin levels determined on day 1 of ICU admission did not
relate to APACHE or SOFA scores (data not shown) or duration
of stay in ICU or in hospital, but for the whole group, the ICU
stay correlated significantly with hospital stay (80 pairs analyzed,
r = 0.6, p< 0.0001). In other studies, depressed C3 levels found in
sepsis were not related to mortality or complications such as pneu-
monia and hemorrhage (13), but decreased C3 levels were linked
to increased hospital stay (14). Therefore, a subgroup analysis was
performed for very low properdin levels. These were defined as
<7µg/ml, the lower end of the normal range established in this
study. Pathologically low properdin levels on Days 1 and 2 nega-
tively correlated with the duration of intensive care treatment and
overall hospitalization, respectively (Figures 1A,B).
There are two possible interpretations for these findings: (i) the
decline in properdin levels is a descriptor of severity of sepsis due to
its ability to bind to LPS of different pathogens (15) or to damaged
cells (16) and (ii) properdin is involved in the pathophysiological
mechanisms of sepsis.
Recent data indicate that the likely determinants of outcome
from sepsis are the cell phenotypes, which emanate from this
condition in dependence of the level of complement components.
FIGURE 1 | Pathologically low properdin levels in the critically
ill and the relationship to treatment duration. Properdin levels
lower than 7µg/ml, the lowest of the normal range established in
this study, were plotted against duration of intensive care treatment
(A) 36 pairs, p<0.05, and total duration of hospitalization (B) 31
pairs, p<0.005. Spearman correlation coefficients are indicated;
regression lines and 95% confidence bands of the best-fit line are
shown.
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Depressed serum C3 levels have been linked to the emergence
in the critically ill of an immune suppressive Treg population
(14). So, altered complement levels may be a mirror of chang-
ing cell activities selected during the septic immune response (17).
Alternatively, a decline in circulating properdin levels may sig-
nify increased complement usage in septic end organs (18) or on
inflamed endothelium (19).
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